
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1003 | 1003 | 1060 | 1207 | 1849 | - |
Fund Return | 0.27% | 0.27% | 6.01% | 6.47% | 13.08% | - |
Place in category | 47 | 47 | 62 | 28 | 27 | - |
% in Category | 24 | 24 | 47 | 34 | 39 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
JPMorgan Large Cap Growth R6 | 60.59B | -7.73 | 11.64 | 16.41 | ||
JPMorgan Large Cap Growth Select | 24.24B | -7.78 | 11.37 | 16.11 | ||
JPMorgan Equity Income R6 | 20.53B | 2.82 | 6.13 | 9.67 | ||
JPMorgan US Equity R6 | 16.06B | -5.60 | 8.32 | 12.68 | ||
JPMorgan Equity Income Select | 14.36B | 2.76 | 5.86 | 9.39 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Goldman Sachs US Eq Div and Prem In | 1.41B | -3.74 | 7.94 | 10.17 | ||
BlackRock US Opportunities Instl | 1.08B | 2.65 | 5.07 | 7.07 | ||
Shelton Core Value Direct | 814.07M | -3.32 | 7.25 | 8.36 | ||
Goldman Sachs US Eq Div and Premium | 428.6M | -3.69 | 7.87 | 10.05 | ||
BlackRock US Opportunities Inv A | 269.67M | 2.58 | 4.79 | 6.78 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Visa A | US92826C8394 | 1.70 | 333.40 | +2.71% | |
Mastercard | US57636Q1040 | 1.69 | 509.75 | +2.08% | |
Progressive | US7433151039 | 1.67 | 275.64 | +0.90% | |
AbbVie | US00287Y1091 | 1.59 | 175.05 | +0.49% | |
Meta Platforms | US30303M1027 | 1.57 | 543.57 | -0.50% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Strong Sell | Strong Sell |
Technical Indicators | Strong Sell | Strong Sell | Strong Sell |
Summary | Strong Sell | Strong Sell | Strong Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review